Professional antigen-presenting cells infected by MVA-P1A

Professional antigen-presenting cells (APCs) infected by MVA-P1A represent a specialized cellular state utilized in cancer immunotherapy research to stimulate a robust anti-tumor immune response (Source: PubMed, PMID: 14531777). Modified Vaccinia Ankara (MVA) is a highly attenuated viral vector that has been engineered to express the P1A tumor-associated antigen, a well-known model antigen in murine studies (Source: PubMed, PMID: 18490741). When MVA-P1A is administered, it preferentially infects professional APCs such as dendritic cells and macrophages, which then synthesize the P1A protein from the viral template. These APCs process the P1A protein into immunogenic peptides and present them on their surface via Major Histocompatibility Complex (MHC) molecules. This presentation is critical for the activation of P1A-specific cytotoxic T lymphocytes (CTLs), which are capable of recognizing and eliminating tumor cells that express the P1A antigen (Source: PubMed, PMID: 11015561). While P1A is a mouse-specific antigen, this system serves as a paradigm for human vaccines targeting MAGE-type antigens in various cancers. The primary therapeutic interaction involves the MVA-P1A viral construct acting as the drug that modifies the APCs to serve as potent immune activators. Challenges in this approach include the development of neutralizing antibodies against the MVA vector itself, which can limit the effectiveness of booster doses (Source: PubMed, PMID: 15163914).

Other names

MVA-P1A-infected APCsMVA-P1A vaccine-loaded antigen-presenting cellsRecombinant MVA-P1A infected dendritic cells

The MVA-P1A vector infects professional antigen-presenting cells, leading to the intracellular expression, processing, and MHC-mediated presentation of the P1A tumor antigen to prime a specific cytotoxic T-cell response (Source: PubMed, PMID: 14531777).